Gossamer Bio Announced Presentation Of Results Of TORREY FRI Sub-Study At The European Respiratory Society International Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Gossamer Bio, Inc. (NASDAQ:GOSS) announced that data from its functional respiratory imaging (FRI) sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with pulmonary arterial hypertension (PAH) will be presented at the European Respiratory Society International Congress 2023. The presentation will be made by Dr. Roham Zamanian, Professor of Pulmonary and Critical Care Medicine at Stanford University.
September 07, 2023 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gossamer Bio's announcement of the presentation of its Phase 2 TORREY Study results at a major congress could potentially boost investor confidence in the company and its seralutinib product.
The presentation of successful study results at a major congress is generally seen as a positive development, as it indicates that the company's product is making progress in the regulatory process. This could potentially lead to increased investor confidence in the company and its product, which could in turn have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100